Some issues in predicting patient recruitment in multi-centre clinical trials

Andisheh Bakhshi, Stephen Senn*, Alan Phillips

*Corresponding author for this work

    Research output: Contribution to journalArticleResearchpeer-review

    20 Citations (Scopus)

    Abstract

    A key paper in modelling patient recruitment in multi-centre clinical trials is that of Anisimov and Fedorov. They assume that the distribution of the number of patients in a given centre in a completed trial follows a Poisson distribution. In a second stage, the unknown parameter is assumed to come from a Gamma distribution. As is well known, the overall Gamma-Poisson mixture is a negative binomial. For forecasting time to completion, however, it is not the frequency domain that is important, but the time domain and that of Anisimov and Fedorov have also illustrated clearly the links between the two and the way in which a negative binomial in one corresponds to a type VI Pearson distribution in the other. They have also shown how one may use this to forecast time to completion in a trial in progress. However, it is not just necessary to forecast time to completion for trials in progress but also for trials that have yet to start. This suggests that what would be useful would be to add a higher level of the hierarchy: over all trials. We present one possible approach to doing this using an orthogonal parameterization of the Gamma distribution with parameters on the real line. The two parameters are modelled separately. This is illustrated using data from 18 trials. We make suggestions as to how this method could be applied in practice.

    Original languageEnglish
    Pages (from-to)5458-5468
    Number of pages11
    JournalStatistics in Medicine
    Volume32
    Issue number30
    DOIs
    Publication statusPublished - 30 Dec 2013

    Keywords

    • Empirical Bayes
    • Gamma distribution
    • Negative binomial distribution
    • Poisson distribution

    Fingerprint

    Dive into the research topics of 'Some issues in predicting patient recruitment in multi-centre clinical trials'. Together they form a unique fingerprint.

    Cite this